Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/jcm6020016 http://scihub22266oqcxt.onion/10.3390/jcm6020016 C5332920!5332920!28208757     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28208757&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Med 2017 ; 6 (2): ä Nephropedia Template TP {{tp|p=28208757|t=2017. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) |pdf=|usr=}}{{28208757}} gab.com Text Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) JO: J Clin Med http://www.kidney.de/pget.php?&tw=1&pmid=28208757 #FOAvip Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated and/or T cell-mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the bone marrow niche have now been recognized to be important. Treatment strategies are aimed at the restoration of platelet counts compatible with adequate hemostasis rather than achieving physiological platelet counts. The first line treatments focus on the inhibition of autoantibody production and platelet degradation, whereas second-line treatments include immunosuppressive drugs, such as Rituximab, and splenectomy. Finally, third-line treatments aim to stimulate platelet production by megakaryocytes. This review discusses the pathophysiology of ITP and how the different treatment modalities affect the pathogenic mechanisms. Twit Text FOAVip Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) ????J Clin Med http://www.kidney.de/pget.php?&tw=1&pmid=28208757 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28208757 #FOAvip English Wikipedia <ref>{{Cite pmid|28208757}}</ref> Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) #MMPMID28208757 Zufferey A; Kapur R; Semple JW J Clin Med 2017[Feb]; 6 (2): ä PMID28208757show ga Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated and/or T cell-mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the bone marrow niche have now been recognized to be important. Treatment strategies are aimed at the restoration of platelet counts compatible with adequate hemostasis rather than achieving physiological platelet counts. The first line treatments focus on the inhibition of autoantibody production and platelet degradation, whereas second-line treatments include immunosuppressive drugs, such as Rituximab, and splenectomy. Finally, third-line treatments aim to stimulate platelet production by megakaryocytes. This review discusses the pathophysiology of ITP and how the different treatment modalities affect the pathogenic mechanisms. äPathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (IT(epmc).pdf DeepDyve Pubget Overpricing